Eugene Braunwald

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/12016758/eugene-braunwald-publications-by-year.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

22 4,930 19 24 g-index

24 5,470 12.5 4.94 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
22	Aortic Stenosis: Then and Now. Circulation, 2018, 137, 2099-2100	16.7	23
21	Unstable Angina and NonBT Elevation Myocardial Infarction 2012 , 1178-1209		5
20	Clinical Recognition of Acute Coronary Syndromes 2011 , 94-100		
19	Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 297, 1775-83	27.4	372
18	Prognosis in the thrombolysis in myocardial ischemia III registry according to the Braunwald unstable angina pectoris classification. <i>American Journal of Cardiology</i> , 2002 , 90, 821-6	3	15
17	Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. <i>Circulation</i> , 2002 , 105, 1760-3	16.7	562
16	Acute coronary syndrome without ST elevation: implementation of new guidelines. <i>Lancet, The</i> , 2001 , 358, 1533-8	40	97
15	Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. <i>Circulation</i> , 2000 , 101, 239-43	16.7	218
14	Thrombolytic therapy for patients with myocardial infarction who are older than 75 years. Do the risks outweigh the benefits?. <i>Circulation</i> , 2000 , 101, 2224-6	16.7	27
13	Redefining medical treatment in the management of unstable angina. <i>American Journal of Medicine</i> , 2000 , 108, 41-53	2.4	43
12	A classification of unstable angina revisited. <i>Circulation</i> , 2000 , 102, 118-22	16.7	280
11	ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With	15.1	731
10	Unstable Angina). <i>Journal of the American College of Cardiology</i> , 2000 , 36, 970-1062 Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. <i>Journal of the American College of Cardiology</i> , 2000 , 36, 1812-7	15.1	187
9	C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 1998 , 31, 1460-5	15.1	626
8	Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. <i>American Heart Journal</i> , 1998 , 135, S56-66	4.9	8
7	Aortic stenosis. <i>Circulation</i> , 1968 , 38, 61-7	16.7	730
6	Effective closure of the mitral valve without atrial systole. <i>Circulation</i> , 1966 , 33, 404-9	16.7	29

LIST OF PUBLICATIONS

5	SYMPOSIUM ON CARDIAC ARRHYTHMIAS. INTRODUCTION WITH COMMENTS ON THE HEMODYNAMIC SIGNIFICANCE OF ATRIAL SYSTOLE. <i>American Journal of Medicine</i> , 1964 , 37, 665-9	2.4	103
4	The ineffectiveness of an inotropic agent, mephentermine (Wyamine), in the treatment of congestive heart failure. <i>American Heart Journal</i> , 1961 , 62, 301-3	4.9	7
3	Studies on Starling & Law of the Heart. Circulation, 1961, 24, 633-642	16.7	346
2	The direct effects of norepinephrine, epinephrine, and methoxamine on myocardial contractile force in man. <i>Circulation</i> , 1960 , 22, 1125-32	16.7	103
1	The effect of mephentermine sulfate on myocardial oxygen consumption, myocardial efficiency and peripheral vascular resistance. <i>American Journal of Medicine</i> , 1958 , 24, 871-81	2.4	44